Platin-DRP® scores were strongly associated with improved survival in advanced NSCLC patients treated with platinum-based chemotherapy, with high-score patients showing a median overall survival of 16.9 months. The biomarker's utility spans both cisplatin and carboplatin regimens.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.